Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend

Overview

• Swiss antibody drug conjugate firm's Q4 net income beat analyst expectations

• Q4 net product revenue rose to $22.3 mln, driven by stable demand and higher prices

• Company amended HealthCare Royalty financing for greater strategic flexibility

Outlook

• Company anticipates cash runway extending into 2028

Result Drivers

• REVENUE GROWTH - Q4 net product revenue increased due to stable demand and higher prices

• R&D EXPENSES - Decrease in R&D expenses due to reduced spending on discontinued programs and completion of certain activities

• STRATEGIC FLEXIBILITY - Amended HealthCare Royalty financing agreement enhances strategic flexibility

Company press release: ID:nPn9PTGXxa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for ADC Therapeutics SA is $8.00, about 89.1% above its March 9 closing price of $4.23

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.